Plain-English translation of NCT05351593 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether combining two medications— and —can help treat brain lymphoma that has come back after previous treatment. Brain lymphoma is a rare cancer that occurs in the brain, spinal fluid, or eyes. The study wants to find the right dose of these medications and see how well they work together to fight this type of cancer.
Brain lymphoma that returns after initial treatment is very difficult to cure with standard options, and patients urgently need new treatment approaches. This trial explores whether combining these two medications might help reach cancer cells in the brain more effectively than previous treatments.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of on specific days each month (more frequently at the start, then less often over time) and take as a daily pill for 21 days of each treatment cycle. The study has two phases: the first phase finds the safest dose, and the second phase tests how well the treatment works. You will have regular blood tests, imaging scans, and possibly spinal fluid checks to monitor your response and any side effects.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States